Author:
Drew William L.,Piret Jocelyne,Boivin Guy
Publisher
Springer International Publishing
Reference239 articles.
1. Ahmed AM, Brantley JS, Madkan V, Mendoza N, Tyring SK. Managing herpes zoster in immunocompromised patients. Herpes. 2007;14:32–6.
2. Andrei G, Fiten P, Froeyen M, De Clercq E, Opdenakker G, Snoeck R. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther. 2007;12:719–32.
3. Andrei G, Topalis D, Fiten P, McGuigan C, Balzarini J, Opdenakker G, et al. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J Virol. 2012;86:2641–52.
4. Andrei G, Georgala A, Topalis D, Fiten P, Aoun M, Opdenakker G, et al. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. J Infect Dis. 2013;207:1295–305.
5. Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107–68.